Treatment algorithm for moderate to severe ulcerative colitis

Swiss Medical Weekly

Volumn 141, Issue JUNE, 2011, Pages

  Manz, Michael ^a   Michetti, Pierre ^b   Seibold, Frank ^c   Rogler, Gerhard ^d   Beglinger, Christoph ^e  

^a St Claraspital AG   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c Spital Bern Tiefenau   (Switzerland)

^d UNIVERSITY OF ZURICH   (Switzerland)

^e UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Consensus conference; Fulminant; Infliximab; Moderate to severe cyclosporin; Steroid dependent; Steroid refractory; Treatment algorithm; Ulcerative colitis

Indexed keywords

5 ACETAMIDOSALICYLIC ACID; AZATHIOPRINE; CYCLOSPORIN; HYDROCORTISONE; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHYLPREDNISOLONE; PREDNISONE; TACROLIMUS;

ALGORITHM; BLOOD CELL COUNT; CHOLESTEROL BLOOD LEVEL; CLOSTRIDIUM DIFFICILE; COLON RESECTION; CORTICOSTEROID THERAPY; CYTOMEGALOVIRUS INFECTION; DRUG DEPENDENCE; DRUG DOSE INCREASE; DRUG TREATMENT FAILURE; FECES CULTURE; HUMAN; HYPOMAGNESEMIA; IMMUNOSUPPRESSIVE TREATMENT; MAINTENANCE THERAPY; MORBIDITY; MORTALITY; PNEUMOCYSTIS JIROVECI; PROPHYLAXIS; REMISSION; REVIEW; SIGMOIDOSCOPY; SURGERY; TREATMENT INDICATION; ULCERATIVE COLITIS; HOSPITALIZATION; PATHOLOGY;

ALGORITHMS; COLITIS, ULCERATIVE; HUMANS; SEVERITY OF ILLNESS INDEX;

EID: 79960255932     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: 10.4414/smw.2011.13235     Document Type: Review

References (58)

1. Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Canadian journal of gastroenterology = Journal canadien de gastroenterologie. 2005;19(Suppl A):5-36.
2. Kucharzik T, Maaser C, Lugering A, Kagnoff M, Mayer L, Targan S, et al. Recent understanding of IBD pathogenesis: implications for future therapies. Inflamm Bowel Dis. 2006;12(11):1068-83.
3. Rahimi R, Nikfar S, Abdollahi M. Meta-analysis technique confirms the effectiveness of anti-TNF-alpha in the management of active ulcerative colitis when administered in combination with corticosteroids. Med Sci Monit. 2007;13(7):PI13-8. (Pubitemid 47037680)
4. Rahimi R, Nikfar S, Larijani B, Abdollahi M. A review on the role of antioxidants in the management of diabetes and its complications. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2005;59(7):365-73.
5. Rezaie A, Khalaj S, Shabihkhani M, Nikfar S, Zamani MJ, Mohammadirad A, et al. Study on the correlations among disease activity index and salivary transforming growth factor-beta 1 and nitric oxide in ulcerative colitis patients. Ann N Y Acad Sci. 2007;1095:305-14. (Pubitemid 47092462)
6. Jahanshahi G, Motavasel V, Rezaie A, Hashtroudi AA, Daryani NE, Abdollahi M. Alterations in antioxidant power and levels of epidermal growth factor and nitric oxide in saliva of patients with inflammatory bowel diseases. Dig Dis Sci. 2004;49(11-12):1752-7. (Pubitemid 40228532)
7. Rezaie A, Parker RD, Abdollahi M. Oxidative stress and pathogenesis of inflammatory bowel disease: an epiphenomenon or the cause? Dig Dis Sci. 2007;52(9):2015-21. (Pubitemid 47246507)
8. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007;369(9573):1641-57. (Pubitemid 46722637)
9. E.F. Stange SPLT, S. Vermeire, W. Reinisch, K. Geboes, A. Barakauskiene, R. Feakins, et al., for the European Crohn's and Colitis Organisation (ECCO). European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis. Journal of Crohn's and Colitis. 2008;2(1):1-23.
10. D'Haens G, Sandborn WJ, Feagan BG, Geboes K, Hanauer SB, Irvine EJ, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007;132(2):763-86.
11. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. British medical journal. 1955;2(4947):1041-8.
12. Farmer RG, Easley KA, Rankin GB. Clinical patterns, natural history, and progression of ulcerative colitis. A long-term follow-up of 1116 patients. Dig Dis Sci. 1993;38(6):1137-46. (Pubitemid 23175139)
13. Flatmark A, Fretheim B, Gjone E. Early colectomy in severe ulcerative colitis. Scand J Gastroenterol. 1975;10(4):427-31.
14. Sonnenberg A. Time trends of mortality from Crohn's disease and ulcerative colitis. Int J Epidemiol. 2007;36(4):890-9. (Pubitemid 47394159)
15. Travis SPL, Lémann M, Øresland T, Bemelman WA, Chowers Y, Colombel JF, et al., for the European Crohn's and Colitis Organisation (ECCO) European evidence-based Consensus on the management of ulcerative colitis: Current management. Journal of Crohn's and Colitis. 2008;2(1):24-62. (Pubitemid 351179488)
16. Ng SC, Kamm MA. Therapeutic strategies for the management of ulcerative colitis. Inflamm Bowel Dis. 2009;15(6):935-50.
17. Panaccione R, Rutgeerts P, Sandborn WJ, Feagan B, Schreiber S, Ghosh S. Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2008;28(6):674-88.
18. Carter MJ, Lobo AJ, Travis SP. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2004;53(Suppl 5):V1-16.
19. Hoffmann JC, Zeitz M, Bischoff SC, Brambs HJ, Bruch HP, Buhr HJ, et al. Diagnosis and therapy of ulcerative colitis: results of an evidence based consensus conference by the German society of Digestive and Metabolic Diseases and the competence network on inflammatory bowel disease. Z Gastroenterol. 2004;42(9):979-83. (Pubitemid 39625605)
20. Travis SPL, Stange EF, Lémann M M, Øresland T, Bemelman WA, Chowers Y, et al. European evidence-based Consensus on the management of ulcerative colitis: Current management. Journal of Crohn's and Colitis. 2008;2(1):24-62. (Pubitemid 351179488)
21. Marteau P, Probert CS, Lindgren S, Gassul M, Tan TG, Dignass A, et al. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut. 2005;54(7):960-5. (Pubitemid 40873909)
22. Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane database of systematic reviews (Online). 2006(2):CD000543.
23. Lichtenstein GR, Sbreu MT, Cohen R, Tremaine W. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Revista de gastroenterologia de Mexico. 2006;71(3):351-401.
24. Ho GT, Chiam P, Drummond H, Loane J, Arnott ID, Satsangi J. The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5-year UK inception cohort. Aliment Pharmacol Ther. 2006;24(2):319-30. (Pubitemid 43972900)
25. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; preliminary report on a therapeutic trial. British medical journal. 1954;2(4884):375-8.
26. Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane database of systematic reviews (Online). 2006(2):CD000544.
27. Bebb JR, Scott BB. How effective are the usual treatments for ulcerative colitis? Aliment Pharmacol Ther. 2004;20(2):143-9. (Pubitemid 38998211)
28. Kane SV, Bjorkman DJ. The efficacy of oral 5-ASAs in the treatment of active ulcerative colitis: a systematic review. Rev Gastroenterol Dis. 2003 Fall;3(4):210-8. (Pubitemid 37540676)
29. Kirk AP, Lennard-Jones JE. Controlled trial of azathioprine in chronic ulcerative colitis. British medical journal (Clinical research ed. 1982;284(6325):1291-2.
30. Ardizzone S, Maconi G, Russo A, Imbesi V, Colombo E, Bianchi Porro G. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut. 2006;55(1):47-53. (Pubitemid 41820634)
31. Stange EF, Travis SPL, Vermeire S, Reinisch W, Geboes K, Barakauskiene A, et al. European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis. 2008 03/01;2(1):1-23.
32. Dimitroulia E, Spanakis N, Konstantinidou AE, Legakis NJ, Tsakris A. Frequent detection of cytomegalovirus in the intestine of patients with inflammatory bowel disease. Inflamm Bowel Dis. 2006;12 (9):879-84. (Pubitemid 44352715)
33. Matsuoka K, Iwao Y, Mori T, Sakuraba A, Yajima T, Hisamatsu T, et al. Cytomegalovirus is frequently reactivated and disappears without antiviral agents in ulcerative colitis patients. Am J Gastroenterol. 2007;102(2):331-7. (Pubitemid 46160547)
34. Bruns T, Stallmach A. Drug monitoring in inflammatory bowel disease: helpful or dispensable? Dig Dis. 2009;27(3):394-403.
35. Teml A, Schaeffeler E, Herrlinger KR, Klotz U, Schwab M. Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing. Clin Pharmacokinet. 2007;46(3):187-208. (Pubitemid 46425646)
36. Hindorf U, Lindqvist M, Peterson C, Soderkvist P, Strom M, Hjortswang H, et al. Pharmacogenetics during standardised initiation of thiopurine treatment in inflammatory bowel disease. Gut. 2006;55 (10):1423-31. (Pubitemid 44476786)
37. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353(23):2462-76. (Pubitemid 41770166)
38. Fellermann K, Tanko Z, Herrlinger KR, Witthoeft T, Homann N, Bruening A, et al. Response of refractory colitis to intravenous or oral tacrolimus (FK506). Inflamm Bowel Dis. 2002;8(5):317-24.
39. Ogata H, Matsui T, Nakamura M, Iida M, Takazoe M, Suzuki Y, et al. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut. 2006;55(9):1255-62. (Pubitemid 44277355)
40. Sands BE, Kaplan GG. The role of TNFalpha in ulcerative colitis. J Clin Pharmacol. 2007;47(8):930-41.
41. Truelove SC, Jewell DP. Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet. 1974;1(7866):1067-70.
42. Rosenberg W, Ireland A, Jewell DP. High-dose methylprednisolone in the treatment of active ulcerative colitis. J Clin Gastroenterol. 1990;12(1):40-1. (Pubitemid 20056512)
43. Turner D, Walsh CM, Steinhart AH, Griffiths AM. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol. 2007;5 (1):103-10. (Pubitemid 46096828)
44. Van Assche G, D'Haens G, Noman M, Vermeire S, Hiele M, Asnong K, et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology. 2003;125(4):1025-31. (Pubitemid 37193449)
45. Arts J, D'Haens G, Zeegers M, Van Assche G, Hiele M, D'Hoore A, et al. Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis. Inflamm Bowel Dis. 2004;10(2):73-8. (Pubitemid 38332164)
46. Cohen RD, Stein R, Hanauer SB. Intravenous cyclosporin in ulcerative colitis: a five-year experience. Am J Gastroenterol. 1999;94(6):1587-92. (Pubitemid 29260450)
47. Epple HJ. Therapy- and non-therapy-dependent infectious complications in inflammatory bowel disease. Dig Dis. 2009;27(4):555-9.
48. Ferrante M, Vermeire S, Katsanos KH, Noman M, Van Assche G, Schnitzler F, et al. Predictors of early response to infliximab in patients with ulcerative colitis. Inflamm Bowel Dis. 2007;13(2):123-8. (Pubitemid 46806219)
49. Gisbert JP, Gonzalez-Lama Y, Mate J. Systematic review: Infliximab therapy in ulcerative colitis. Aliment Pharmacol Ther. 2007;25(1):19-37. (Pubitemid 44902861)
50. Jakobovits SL, Jewell DP, Travis SP. Infliximab for the treatment of ulcerative colitis: outcomes in Oxford from 2000 to 2006. Aliment Pharmacol Ther. 2007;25(9):1055-60. (Pubitemid 46587696)
51. Jarnerot G, Hertervig E, Friis-Liby I, Blomquist L, Karlen P, Granno C, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology. 2005;128(7):1805-11. (Pubitemid 40824691)
52. Kohn A, Daperno M, Armuzzi A, Cappello M, Biancone L, Orlando A, et al. Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-up. Aliment Pharmacol Ther. 2007;26(5):747-56. (Pubitemid 47246204)
53. Manosa M, Lopez San Roman A, Garcia-Planella E, Bastida G, Hinojosa J, Gonzalez-Lama Y, et al. Infliximab rescue therapy after cyclosporin failure in steroid-refractory ulcerative colitis. Digestion. 2009;80(1):30-5.
54. Lees CW, Heys D, Ho GT, Noble CL, Shand AG, Mowat C, et al. A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitis. Aliment Pharmacol Ther. 2007;26(3):411-9. (Pubitemid 47063146)
55. Moskovitz DN, Van Assche G, Maenhout B, Arts J, Ferrante M, Vermeire S, et al. Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis. Clin Gastroenterol Hepatol. 2006;4(6):760-5. (Pubitemid 43833506)
56. Moss AC, Peppercorn MA. Steroid-refractory severe ulcerative colitis: what are the available treatment options? Drugs. 2008;68(9):1157-67. (Pubitemid 351822109)
57. Baumgart DC, Macdonald JK, Feagan B. Tacrolimus (FK506) for induction of remission in refractory ulcerative colitis. Cochrane database of systematic reviews (Online). 2008(3):CD007216.
58. Baumgart DC, Pintoffl JP, Sturm A, Wiedenmann B, Dignass AU. Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease - 2a long-term follow-up. Am J Gastroenterol. 2006;101(5):1048-56. (Pubitemid 43725319)